Zhongchong Sino Biological Technology Co.,Ltd
Zhong Chong Xinnuo Biotechnology Taizhou Co., Ltd. is a national high-tech enterprise engaged in research and development of new veterinary biological products, transformation of results, vaccine quality evaluation, research and development of diagnostic preparations, technical services and scientific and technological consulting. The company is located in Taizhou China Medical City, invested and constructed by Beijing Xinnuo Jinghe Biological Technology Co., Ltd., with a registered capital of 50 million yuan and an area of 23 acres.
The company has obtained the China National Accreditation Service for Conformity Assessment (CNAS) certificate. It is a CNAS laboratory for animal vaccine quality evaluation of domestic enterprises. The platform operates a total of 43 CNAS accredited testing parameters. It can issue international mutual recognition CNAS reports, which involve vaccine laboratory testing, Clinical safety and efficacy evaluation; pig and poultry disease surveillance, etc., provide public and fair third-party testing support for animal disease prevention and control and vaccine development in line with international standards.
In 2016, the company established a pre-clinical safety evaluation center for new drugs in China Medical City in cooperation with Taizhou Medical Park and Chengdu Anping Center. Its main business is the safety of professional human drugs (chemical drugs, antibodies, biotechnology drugs, new preparation drugs, traditional Chinese medicine, etc.) Evaluation, technology transfer, technology promotion, technology consulting services, product characteristic inspection services.
In 2018, the company was approved as the key laboratory for the safety evaluation of agricultural products and livestock and poultry inputs of the Ministry of Agriculture and Rural Areas, mainly researching safety evaluation animal models and residue limit standards, establishing methods and providing testing services for the safety inspection of agricultural products and food animals
The company has undertaken three 13th Five-Year National Priorities, including "Integrated and Demonstration Research on Integrated Prevention and Control Technology of Newcastle Disease in Breeding Farms", "Research on Quality Evaluation Standards of Veterinary Biological Products and Testing Reagents", and "Research on New Technology of Avian Influenza Immune Prevention and Control" R&D plan project, presided over the "Chinese Veterinary Pharmacopoeia" (2015 version) "injection white oil quality standards" and "general requirements for raw materials of animal origin", (2020 version) "general requirements for animal vaccine safety inspection", "viscosity determination method" And many other national standards.
As of April 2019, the company has "Recombinant Newcastle Disease Virus, Avian Influenza Virus (H9 Subtype) Combined Inactivated Vaccine (A-Ⅶ strain + WJ57 strain)", "Newcastle Disease, Infectious Bronchitis Combined Live Vaccine" (La Sota strain + QX87 strain)", "chicken Marek's disease gene deletion live vaccine (SC9-1) strain" and other four products obtained new veterinary medicine certificates. Among them, under the leadership of Academician Liu Xiufan of Yangzhou University, he successfully developed the "Recombinant Newcastle Disease Virus Inactivated Vaccine (A-Ⅶ Strain)". In 2014, he obtained the national first-class new veterinary drug registration certificate and was selected for the National "Twelfth Five-Year" Science and Technology Achievement Exhibition. Won the first prize of scientific and technological progress of the Ministry of Education, and won the second prize of national invention in 2019.
In October 2019, the company's entry "Development of a new animal vaccine development, transformation and evaluation technology integration platform" was shortlisted in the final group of the 8th China Innovation and Entrepreneurship Competition and won the Excellent Enterprise Award.
The company has established industry-university-research cooperation relations with scientific research institutes such as Yangzhou University, Shandong Agricultural University, Harbin Veterinary Research Institute, Jiangsu Vocational College of Agriculture, Animal Husbandry and Technology, South China Agricultural University, etc., and with Qingdao Yibang Bioengineering Co., Ltd. The company, Tianjin Ruipu Biotechnology Co., Ltd. and other domestic vaccine companies, the world's third largest breeding company, Beijing Huaduyukou Poultry Industry Co., Ltd., Huayu Agricultural Technology Co., Ltd. and other leading breeding enterprises have established good cooperation. Relationship, through the "scientific burden reduction, scientific evaluation" action to achieve scientific use of seedlings, and promote the healthy development of breeding enterprises.
The company is committed to becoming an R&D and evaluation institution that is close to the actual demand for disease prevention and control in China's aquaculture industry, its technical level is in line with international standards, establish an open, efficient and win-win cooperation platform, gather leading talents and advantageous resources, and strengthen and accelerate the industrialization of new products. Ability and process, adhering to the "one world, one health" concept, and working with partners to build a community of life, health, and human destiny.